-- CorMedix Therapeutics (CRMD) 週一宣布，一項評估 Rezzayo 用於預防幹細胞移植患者侵襲性真菌感染的 III 期臨床試驗已達到主要終點。 該公司表示，該試驗的主要終點是第 90 天時真菌感染清除率為 60.7%，而標準抗菌方案組的清除率為 59.0%。 CorMedix 表示，Rezzayo（注射以瑞札芬淨）耐受性良好，安全性良好，對免疫功能低下患者有良好的效益風險比。 CorMedix 股價週一上漲 2.3%。
Price: $7.67, Change: $+0.25, Percent Change: +3.37%
Santana Minerals (ASX:SMI, NZE:SMI) reported steady progress across permitting, financing, and exploration at its Bendigo-Ophir Gold Project in New Zealand's South Island, highlighted by advancing fast-track approvals (FTA), a AU$130 million capital raise, and continued high-grade drilling success at the Rise and Shine deposit, according to a Tuesday filing with the Australian and New Zealand bourses.The company said the FTA process for Bendigo-Ophir remains a priority, with a consent decision set for Oct. 29 and engagement with the FTA expert panel already underway.Key infrastructure milestones include a finalized road access agreement with the Central Otago District Council and the creation of a NZ$1.3 million annual community fund.Operational readiness is advancing through key mining fleet agreements with Komatsu, alongside exploration success at the Rise and Shine deposit, where mineralization has been extended to over 2.2 kilometers with strong high-grade intercepts.The company completed a AU$130 million capital raising alongside a AU$4.1 million share purchase plan, strengthening funding for its predominantly debt-funded development plan, and closed the third quarter with a net cash balance of AU$184 million after payables.
Shanghai Xizhi Technology (HKG:1879) raised HK$2.38 billion in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$183.20 per H-share, the top of the offer price range, according to a Monday after-market filing with the Hong Kong Stock Exchange.The China-based optoelectronic computing company offered 13.8 million H-shares in the global offering.The Hong Kong public offer was 5,784.70 times subscribed, with a final allocation of 2.8 million shares, representing 20% of the total offering.The international offering was 53.83 times subscribed, with a final allocation of 11 million shares, or 80% of the total offering.An over-allocation of 2.1 million shares was made under the global offering.Cornerstone investors, including Alibaba Investment, GIC, Baillie Gifford, BlackRock, Fidelity International, Schroders, Temasek, and CM Shanghai Fund, were allotted a combined 9 million shares, according to the filing.Xizhi Tech is scheduled to debut on the Hong Kong bourse on Tuesday, April 28.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ARE reported Q1 revenue of $671M (-11.5% Y/Y and $25M below consensus) vs. $754M a year ago. Rental income declined 12.1% to $653M, reflecting lower occupancy and significant pricing pressure on lease renewals across the portfolio. Rental rate changes on renewals and re-leasing showed a steep 15.0% decline (-15.8% cash basis), a dramatic reversal from the -5.5% cash renewal rate in Q4 2025. Management updated cash rental rate guidance to -14% to -7%, declining a further 300 bps since February as market conditions deteriorated. We expect continued pressure on re-leasing growth in full-year 2026 as ARE continues to optimize its portfolio of properties amid challenging life science market dynamics. The significant deterioration in renewal spreads from Q4 2025 to Q1 2026 highlights the difficult operating environment facing life science real estate, with both occupancy headwinds and rental rate pressures creating a challenging backdrop for near-term financial performance and cash flow generation.